Moving beyond vegf for anti-angiogenesis strategies in gynecologic cancer

Current Pharmaceutical Design

Volumn 18, Issue 19, 2012, Pages 2713-2719

  Thanapprapasr, Duangmani ^a,b   Hu, Wei ^b   Sood, Anil K ^b,c   Coleman, Robert L ^b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Cervix cancer; Dll4 notch; Endothelial cells; Ezh2; Focal adhesion kinase; Ovarian cancer; Uterine cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DLL4 PROTEIN; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A2 ANTIBODY; EPHRIN RECEPTOR A5 ANTIBODY; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GELATINASE A; GELATINASE B; INTEGRIN; MONOCLONAL ANTIBODY; NOTCH RECEPTOR; OMP 21M18; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ANTIBODY; PROTEIN RET; REGN 421; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MIGRATION; DRUG EFFICACY; ENDOMETRIUM CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UTERINE CERVIX CANCER;

EID: 84862528348     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800626201     Document Type: Review

References (86)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008; 68(6): 771-89.
4. Burger RB, MF, Fleming GF. et al. Phase III trial of bevacizumab in the primary treatment of advanced ovarian, primary peritoneal or fallopian tube cancer: a GOG study. Int J Gynecol Cancer 2010; 20(suppl 2).
5. Pfisterer J, Perret P, Swart AM, et al. ICON 7: A randomized controlled trial of bevacizumab in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Int J Gynecol Cancer 2010; 20 (suppl 2.) http://journals.lww.com/ijgc/Docume...Prague.pdf
6. Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 1992; 358: 690-2.
7. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. Pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992; 89: 5192-6.
8. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003; 116: 1409-16.
9. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Focal adhesion kinase: a promising target for anticancer therapy. Expert Opin Ther Targets 2007; 11: 1315-28.
10. Schwock J, Dhani N, Hedley DW. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 2010; 14: 77-94.
11. Frame MC, Patel H, Serrels B, Lietha D, Eck MJ. The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol 2010; 11: 802-14.
12. Chen TH, Chan PC, Chen CL, Chen HC. Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition. Oncogene 2011; 30: 153-66.
13. Murakami H, Iwashita T, Asai N, Iwata Y, Narumiya S, Takahashi M. Rho-dependent and independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. Oncogene 1999; 18: 1975-82.
14. Plaza-Menacho I, Morandi A, Mologni L, et al. Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem 2011; 286: 17292-302.
15. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14: 627-32.
16. Cary LA, Klinghoffer RA, Sachsenmaier C, Cooper JA. SRC catalytic but not scaffolding function is needed for integrinregulated tyrosine phosphorylation, cell migration, and cell spreading. Mol Cell Biol 2002; 22: 2427-40.
17. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994; 14: 1680-8.
18. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995; 15: 954-63.
19. Calalb MB, Zhang X, Polte TR, Hanks SK. Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun 1996; 228: 662-8.
20. Schlaepfer DD, Hunter T. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Srcfamily protein-tyrosine kinases. Mol Cell Biol 1996; 16: 5623-33.
21. Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG. Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol 2003; 34: 240-5.
22. Van Slambrouck S, Grijelmo C, De Wever O, et al. Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int J Oncol 2007; 31: 1501-8.
23. Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000; 6: 2417-23.
24. Owens LV, Xu L, Dent GA, et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 1996; 3: 100-5.
25. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer a new therapeutic opportunity. Nat Rev Cancer 2005; 5: 505-15.
26. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3kinase/Akt cell survival pathway. J Biol Chem 1999; 274: 20693-703.
27. Tureckova J, Vojtechova M, Krausova M, Sloncova E, Korinek V. Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells. Transl Oncol 2009; 2: 281-90.
28. Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 2006; 12: 3233-7.
29. Haskell H, Natarajan M, Hecker TP, et al. Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin Cancer Res 2003; 9: 2157-65.
30. Judson PL, He X, Cance WG, Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999; 86: 1551-6.
31. Gabriel B, Mildenberger S, Weisser CW, et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004; 24: 921-7.
32. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005; 113: 372-8.
33. Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004; 165: 1087-95.
34. Halder J, Landen CN, Jr., Lutgendorf SK, et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005; 11: 8829-36.
35. Halder J, Kamat AA, Landen CN, Jr., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006; 12: 4916-24.
36. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67: 10976-83.
37. Shahzad MM, Lu C, Lee JW, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009; 8: 1027-34.
38. Lane D, Goncharenko-Khaider N, Rancourt C, Piche A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010; 29: 3519-31.
39. Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010; 120: 1515-23.
40. Livasy CA, Moore D, Cance WG, Lininger RA. Focal adhesion kinase overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 2004; 12: 342-5.
41. Gabriel B, Hasenburg A, Waizenegger M, Orlowska-Volk M, Stickeler E, zur Hausen A. Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study. Int J Gynecol Cancer 2009; 19: 1221-5.
42. Park DW, Choi KC, MacCalman CD, Leung PC. Gonadotropin releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase. Reprod Biol Endocrinol 2009; 7: 81.
43. McCormack SJ, Brazinski SE, Moore JL, Jr., Werness BA, Goldstein DJ. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 1997; 15: 265-74.
44. Moon HS, Park WI, Choi EA, Chung HW, Kim SC. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer 2003; 13: 640-6.
45. Perry BC, Wang S, Basson MD. Extracellular pressure stimulates adhesion of sarcoma cells via activation of focal adhesion kinase and Akt. Am J Surg 2010; 200: 610-4.
46. Daoud G, Le bellego F, Lafond J. PP2 regulates human trophoblast cells differentiation by activating p38 and ERK1/2 and inhibiting FAK activation. Placenta 2008; 29: 862-70.
47. Fang LQ, Zhang H, Ding XY, et al. Mouse trophoblastic cells exhibit a dominant invasiveness phenotype over cancer cells. Cancer Lett 2010; 299: 111-8.
48. Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67: 1757-68.
49. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11.
50. Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185-97.
51. Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008; 214: 295-300.
52. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007; 17: 52-9.
53. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-49.
54. Patel NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res (an official journal of the American Association for Cancer Research) 2006; 12: 4836-44.
55. Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007; 13: 389-95.
56. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444: 1032-7.
57. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444: 1083-7.
58. Li JL, Sainson RC, Shi W, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007; 67: 11244-53.
59. Hu W, Lu C, Stone RL, et al. Biologic role of tumor and endothelial delta-like ligand 4 in ovarian cancer. Gynecol Oncol 2011; 120: S35-36.
60. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007; 67: 1879-82.
61. Kolibaba K, Drunker B. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997; 1997: F217-48.
62. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol 1997; 9: 608-15.
63. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004; 10: 5145-50.
64. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003; 162: 1037-42.
65. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focaladhesion-kinase dephosphorylation. Nat Cell Biol 2000; 2: 62-9.
66. Walker-Daniels J, Riese DJ, 2nd, Kinch MS. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 2002; 1: 79-87.
67. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res 2000; 10: 401-11.
68. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 2301-6.
69. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999; 41: 275-80.
70. D'Amico TA, Aloia TA, Moore MB, et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001; 72: 1144-8.
71. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000; 19: 6043-52.
72. Macrae M, Neve RM, Rodriguez-Viciana P, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005; 8: 111-8.
73. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007; 109: 332-40.
74. Cheng N, Brantley DM, Liu H, et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002; 1: 2-11.
75. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5: 194-204.
76. Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61: 3250-5.
77. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002; 62: 2840-7.
78. Landen CN, Jr., Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006; 98: 1558-70.
79. Alves PM, Faure O, Graff-Dubois S, et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201 restricted epitopes. Cancer Res 2003; 63: 8476-80.
80. Cheng N, Brantley D, Fang WB, et al. Inhibition of VEGF dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 2003; 5: 445-56.
81. Brantley EA. Soluble EphA receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011-26.
82. Dobrzanski P, Hunter K, Jones-Bolin S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004; 64: 910-9.
83. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65: 6910-18.
84. Annunziata CM, Kohn EC, Lorusso P, et al., Phase 1, open label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 2012 Feb.
85. Wesa AK, Herrem CJ, Mandic M, et al. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J Immunol 2008; 181: 7721-7.
86. Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 777-88.